부산대학교 도서관

To authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1479-828X.2009.01016.x Byline: Wei WANG (1), Viet DO (1), Russell HOGG (2), Gerard WAIN (2), Alison BRAND (2), Colin BULL (1), Annie STENLAKE (2), Val GEBSKI (1,3) Keywords: cytoreductive surgery; pattern of failure; survival; pelvic radiotherapy; uterine papillary serous carcinoma; vaginal brachytherapy Abstract: Objective: To evaluate the outcome in patients with uterine papillary serous carcinoma (UPSC). Methods: A retrospective review of women treated for UPSC between 1995 and 2006 in Westmead Hospital, Sydney. The patients were treated with total abdominal hysterectomy, bilateral salpingo-oophorectomy and surgical staging. The majority of the patients had platinum-based adjuvant chemotherapy and radiotherapy. Sites of initial recurrence were documented. Overall survival (OS) and progression free survival (PFS) were estimated using Kaplan-Meier method. Univariate and multivariate analysis was performed using Cox regression analysis to test the effects of multiple prognostic factors on survival. Results: Two-year and five-year OS was 65% and 43%. The median OS was 39 months. Two-year and five-year PFS was 60% and 35%. Macroscopic residual disease at the completion of surgery was the only significant prognostic factor associated with worse OS on both univariate and multivariate analysis (P < 0.001). The median OS was only 11 months if patients had macroscopic residual disease, and all patients died within 18 months despite adjuvant therapies. Twenty-one patients relapsed. The site(s) of initial recurrence were: vagina (five patients), pelvic lymph nodes (four patients), abdomen (11 patients), para-aortic lymph nodes (six patients), inguinal lymph nodes (two patients) and distant metastases in seven patients. Only one of 16 patients who received vaginal brachytherapy failed in the vagina, but three of seven patients who received external beam pelvic radiotherapy failed in the vagina. Conclusion: We recommend optimal cytoreduction surgery with the aim of leaving no macroscopic disease at the end of the operation. Vaginal brachytherapy should be considered as a component of adjuvant radiotherapy. Abdominal failure was the commonest mode of failure in our cohort of patients. Author Affiliation: (1)Radiation Oncology (2)Gynaecology Oncology, Westmead Hospital (3)NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia Article History: Received 19 December 2008; accepted 21 March 2009. Article note: Correspondence: Dr Wei Wang, Department of Radiation Oncology, Westmead Hospital, Sydney, NSW 2, Australia. Email: wangwei78@hotmail.com